Publications by authors named "E Roca"
Introduction: The advocacy Women Against Lung Cancer in Europe (WALCE) promoted the European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) and provided a free-of-charge molecular profiling platform for NSCLC sample characterization with the aim of increasing the detection of targetable drivers and improving patients' access to clinical trials in Europe.
Methods: From January 2021 to December 2023, 20 centers located at five different European countries (Greece, Slovenia, Romania, Albania, and Italy) joined EPROPA, with 555 patients with advanced NSCLC registered to the program. Anonymized patients' clinical-pathological data were shared through the EPROPA web platform and tissue samples were collected at the Molecular Pathology Unit of the Reference Center (University of Turin) for molecular analyses.
Article Synopsis
- - Pleural diseases, particularly malignant pleural mesothelioma (PM), pose significant global health challenges, affecting about one million people annually, primarily linked to asbestos exposure and often lead to poor patient outcomes.
- - Timely and accurate diagnosis of PM is critical but complicated by the need for skilled operators and adequate facilities; traditional methods like cytology aren’t effective, making tissue biopsies essential for accurate diagnosis.
- - Medical thoracoscopy (MT) and video-assisted thoracoscopy (VATS) are considered the gold standards for diagnosing malignant pleural conditions, enabling both diagnostic and therapeutic interventions, while emphasizing the importance of interdisciplinary collaboration for optimal patient care.
Article Synopsis
- The MET exon 14 skipping mutation is a rare occurrence in non-small-cell lung cancer (NSCLC), found in 3%-4% of cases, and this study analyzes the characteristics and treatment outcomes for patients from the Italian ATLAS registry.
- In a cohort of 146 advanced METex14 NSCLC patients, treated primarily with MET inhibitors capmatinib (38%) and tepotinib (23%), the response rate was 37% and the disease control rate was 62%, with median progression-free survival of 6.6 months and overall survival of 10.7 months.
- Adverse effects were noted in 12% of patients, with serious complications requiring dose modifications in a small percentage, indicating
Background: Osimertinib represents the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring classical epidermal growth factor receptor (EGFR) mutations, constituting 80%-90% of all EGFR alterations. In the remaining cases, an assorted group of uncommon alterations of EGFR (uEGFR) can be detected, which confer variable sensitivity to previous generations of EGFR inhibitors, overall with lower therapeutic activity. Data on osimertinib in this setting are limited and strongly warranted.
View Article and Find Full Text PDFWhile data show improvement in terms of educational access, dropout rates are significant in many countries. In Spain, 28% of students drop out of school without finishing secondary school, more than double the EU average. Thus, extensive research has shown the consequences of the dropout phenomenon, including negative effects on employment, welfare dependency, as well as health and emotional problems.
View Article and Find Full Text PDF